RecruitingPhase 1NCT05492682

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3

Sponsor

Valo Therapeutics Oy

Enrollment

15 participants

Start Date

Feb 2, 2023

Study Type

INTERVENTIONAL

Conditions

Triple-Negative Breast Cancer Colorectal, Cancer Sarcoma Non-small Cell Lung Cancer Osteosarcoma Melanoma (Skin)Synovial Sarcoma Myxoid Liposarcoma

Summary

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cyclophosphamide, a drug called Pembrolizumab, and others for people with colorectal, cancer, melanoma (skin), and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPeptiCRAd-1

All patients will receive PeptiCRAd-1.

DRUGCyclophosphamide

All patients will be pre-treated with one single dose of Cyclophosphamide.

DRUGPembrolizumab

All patients will receive 6 doses of Pembrolizumab within the study.

Locations(7)

Krankenhaus Nordwest

Frankfurt, Germany

National Center for Tumor Diseases

Heidelberg, Germany

Universitätsklinikum Tübingen

Tübingen, Germany

Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS

Candiolo, Italy

IRCCS Istituto Clinico Humanitas

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

Università di Napoli Federico II

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05492682

Related Trials

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

NCT0536331949 locations

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT0706665720 locations

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT0743182772 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695199 locations